GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
4

4Basebio 4BB.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

525.00p

-0.94%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

4Basebio — daily 4BB

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View 4Basebio on TradingView ↗
Market value
£81.6m
Last close × shares
Volume
1k
Shares, 9 Nov 2026

About 4Basebio

Its shares trade on LSE under the ticker 4BB.L. It has been listed since 17 February 2021. In the fiscal year to 31 December 2025, it reported revenue of £1.7m and a net loss of £16.9m. At that date it held total assets of £29.5m and shareholders' equity of £10.1m.

4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The company is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. The company is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. The company has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. The company is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.

Figures and description from our data supplier, not checked against the company's own report.

More about 4Basebio →

Latest on 4Basebio

Our reporting

We have not reported on 4Basebio yet.

Next results

2 Jun 2027

Due on 2 Jun 2027. Analysts expect earnings of -0.60 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is 4Basebio's ticker?

4Basebio trades as 4BB.L on LSE, under ISIN GB00BMCLYF79.

What was 4Basebio's last closing price?

525.00p on 9 Nov 2026. The figure is in GBp and is never converted.

When does 4Basebio next report results?

Results are expected on 2 Jun 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.